DAIC

MAY 31, 2024

Joaquin Duato , Chairman and Chief Executive Officer of Johnson & Johnson, said, “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory of cardiovascular disease, one of the leading causes of death globally.

Peripheral Arterial Disease 104

Peripheral Arterial Disease Innovation Coronary Artery Disease Cardiovascular Interventions 104

DAIC

MARCH 27, 2024

The company reports this broadens the use of the novel bioadaptor platform technology beyond the treatment of coronary artery disease. Peripheral arterial disease ( PAD ) affects more than 200 million people worldwide. Glob Heart. 2014;9(1):145-158 e121. 2013;382(9901):1329-1340.

Peripheral Arterial Disease 111

Peripheral Arterial Disease Ischemia Technology Coronary Artery Disease 111

DAIC

MARCH 20, 2024

CLTI is the most severe form of peripheral arterial disease (PAD), estimated to affect 11% of the 200 million people suffering from PAD globally. The Freesolve BTK RMS is designed for individuals suffering from chronic limb-threatening ischemia (CLTI). For more information: www.biotronik.com References: 1 Kwong M.,

Peripheral Arterial Disease 105

Peripheral Arterial Disease Innovation Technology Coronary Artery Disease 105

DAIC

MAY 8, 2024

1 Atherosclerosis is a systemic disease that affects multiple vascular regions and is particularly severe in PAD patients, where up to 80 percent suffer from concurrent coronary artery disease (CAD), historically linked with a mortality rate exceeding 50 percent within five years. Journal of Vascular Surgery, Mar.

Coronary Artery Disease 111

Coronary Artery Disease Chest Pain Ischemia Myocardial Infarction 111

DAIC

JUNE 18, 2024

The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease. The DynamX bioadaptor has a novel design and mechanism of action designed to return the diseased vessel to a more normal condition, through three distinct phases.

Coronary Artery Disease 105

Coronary Artery Disease Technology Stents Stent 105

DAIC

APRIL 5, 2024

With the addition of Shockwave, Johnson & Johnson will expand its MedTech cardiovascular portfolio into two of the highest-growth, innovation-oriented segments of cardiovascular intervention – coronary artery disease (CAD) and peripheral artery disease (PAD).

Cardiovascular Interventions 105

Cardiovascular Interventions Technology Innovation Angina 105